Tarlige selectively binds to the α 2 δ -1 subunit of voltage dependent calcium channels to regulate calcium ion influx, thereby reducing the release of excitatory neurotransmitters and effectively relieving neuropathic pain.

1、 Drug name

Tarlige, commonly known as Mirogabalin Besilante, is a neuropathic pain treatment drug.

II. Indications

Used for treating neuropathic pain.

3、 Specifications

5mg * 100 tablets/box.

4、 Main components

The main ingredient is Milo Bahrain benzenesulfonate, with each tablet containing 5mg of Milo Bahrain.

5、 Usage and dosage

The initial dose for adults is usually 5mg once, taken orally twice a day. Afterwards, gradually increase the dosage by 5mg each time with an interval of more than one week, and maintain the dose at 10-15 mg once, twice a day. Adjustments can be made according to age and symptoms.

6、 Dose adjustment (for patients with renal dysfunction)

Adjust dosage based on creatinine clearance rate (CLcr):

1. Mild (CLcr 60-90mL/min): 10-30mg per day, initially 5mg once, twice a day.

2. Moderate (CLcr 30-60mL/min): 5-15mg per day, initially 2.5mg once, twice a day.

3. Severe (CLcr<30mL/min, including hemodialysis patients): 2.5-7.5mg per day, initially 2.5mg once a day, once a day.

4. Starting from low doses, if the efficacy is insufficient after confirming tolerability, increase the dosage further.

7、 Medication precautions

1. Before and after meals: It can be taken on an empty stomach or after a meal. Taking it after a meal can slightly reduce peak concentration and prolong peak time, but has a small impact on total absorption.

2. Missed dose: It should be taken as soon as possible. If it is close to the next dose, skip it and do not double the dose.

3. Vomiting: If vomiting occurs shortly after taking medication, it is necessary to determine whether to take it again based on the time taken; Long term vomiting requires evaluation of therapeutic efficacy.

4. Sudden discontinuation of medication should be avoided to prevent withdrawal symptoms such as insomnia, nausea, diarrhea, and decreased appetite.

5. During medication, dizziness, drowsiness, and loss of consciousness may occur, and driving or operating dangerous machinery should be avoided.

8、 Medication for special populations

1. Pregnant women: Use only when the benefits of treatment outweigh the risks, animal experiments have shown that it can pass through the placenta.

2. Breastfeeding period: Treatment benefits and breastfeeding benefits should be considered before deciding whether to continue breastfeeding. Animal experiments have shown that breast milk can be obtained.

3. Children: Clinical trials have not yet been conducted, and the safety and efficacy are unclear.

4. Elderly people: Those with decreased kidney function need to adjust the dosage and pay attention to preventing falls caused by dizziness and drowsiness.

9、 Adverse reactions

1. Common side effects include drowsiness, swelling, weight gain, headache, nausea, constipation, dry mouth, blurred vision, etc.

2. Serious adverse reactions (incidence rate<0.1% or unknown):

Loss of consciousness, drowsiness, dizziness (may cause falls, fractures).

Liver function impairment (elevated AST and ALT).

Renal dysfunction.

Visual impairment (amblyopia, diplopia, etc.).

10、 Contraindications

Individuals with a history of allergies to any component of this medication are prohibited from using it.

11、 Drug interactions

1. Combined use with probenecid may enhance the efficacy of this drug, as probenecid inhibits OAT1, OAT3, and UGT, increasing the blood concentration of this drug.

2. Combined use with cimetidine may enhance the efficacy of this drug, as cimetidine inhibits MATE1 and MATE2-K.

3. Co administration with lorazepam or alcohol may exacerbate the decline in attention and balance function.

4. There is no significant pharmacokinetic interaction when used in combination with tramadol.

12、 Storage method

Room temperature storage, valid for 3 years. After opening, OD tablets should be stored against moisture.

Tarligeinformation